Harmony Biosciences (HRMY) Scheduled to Post Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) will issue its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.64 per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.29). Harmony Biosciences had a net margin of 22.16% and a return on equity of 27.49%. The firm had revenue of $168.40 million for the quarter, compared to the consensus estimate of $168.90 million. During the same period in the prior year, the business earned $1.01 EPS. The company's quarterly revenue was up 31.3% compared to the same quarter last year. On average, analysts expect Harmony Biosciences to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Harmony Biosciences Price Performance

HRMY stock traded down $0.50 during trading hours on Tuesday, hitting $28.85. 425,156 shares of the stock traded hands, compared to its average volume of 374,446. The stock has a 50-day simple moving average of $31.76 and a 200 day simple moving average of $30.04. Harmony Biosciences has a one year low of $18.61 and a one year high of $39.26. The company has a market cap of $1.64 billion, a P/E ratio of 13.61, a P/E/G ratio of 0.41 and a beta of 0.73. The company has a current ratio of 2.75, a quick ratio of 2.72 and a debt-to-equity ratio of 0.38.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 11,979 shares of the firm's stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 30.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Mizuho decreased their target price on Harmony Biosciences from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 9th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $49.00 price target on shares of Harmony Biosciences in a research report on Friday, April 12th. Bank of America reiterated an "underperform" rating and issued a $30.00 price target on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. Finally, The Goldman Sachs Group increased their price objective on Harmony Biosciences from $25.00 to $28.00 and gave the stock a "sell" rating in a research note on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.63.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.